Original Paper

Spatial Clusters of Creutzfeldt-Jakob Disease Mortality in Japan between 1995 and 2004
Y. Doi^a, T. Yokoyama^b, M. Sakai^b, Y. Nakamura^c, T. Tango^b, K. Takahashi^b

Departments of
^aEducation and Training Technology, and
^bTechnology Assessment and Biostatistics, National Institute of Public Health, Saitama, and
^cDepartment of Public Health, Jichi Medical University, Tochigi, Japan

Address of Corresponding Author

Neuroepidemiology 2008;30:222-228 (DOI: 10.1159/000126916)

  Key Words

• Creutzfeldt-Jakob disease
• Mortality
• Death certificate
• Flexible scan statistic
• Spatial disease cluster

  Abstract

Background: There is suggested to be a geographical difference in Creutzfeldt-Jakob disease (CJD) mortality in Japan. We performed a study to detect localized clusters and hot-spot areas of deaths from CJD in Japan during the 10-year period from 1995 to 2004. Methods: The diagnosis of CJD was taken from the death certificate (coded as A81.0 in the ICD-10). A total number of 1,168 CJD deaths (500 males and 668 females) were used for analysis using empirical Bayes estimates of standardized mortality ratios and the flexible spatial scan statistic to detect clusters. To detect the most likely cluster, p values were obtained using Monte Carlo hypothesis testing (with p < 0.05 as statistical significance).Results: The most likely cluster of CJD mortality was located in the northwest region from the base of Mt. Fuji, stretching over the two neighboring prefectures of Yamanashi and Shizuoka (relative risk = 2.28, p = 0.021). Some other clusters were detected but were not significant. Conclusions: The present study supports the evidence of geographical clustering of deaths from CJD at a specific location in Japan.

Copyright © 2008 S. Karger AG, Basel

  References

1.

Johnson RT: Prion diseases. Lancet Neurol 2005;4:635-642. 

2.

Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeiro K, Alperovitch A, Poser S, Pocchiari M, Hofman A, Smith PG: A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996;347:921-925. 

3.

The National Creutzfeldt-Jakob Disease Surveillance Unit. http://www.cjd.ed.ac.uk/vcjdworld.htm (accessed December 4, 2007).

4.

Yamada M, Variant CJD Working Group: Creutzfeldt-Jakob disease Surveillance Committee Japan: the first Japanese case of variant Creutzfeldt-Jakob disease showing periodic electroencephalogram. Lancet 2006;367:874. 

5.

Brown P, Preece M, Brandel JP, Sato T, McShane L, Zerr I, Fletcher A, Will RG, Pocchiari M, Cashman NR, d'Aignaux JH, Cervenáková L, Fradkin J, Schonberger LB, Collins SJ: Iatrogenic Creutzfeldt-Jakob disease at the millennium. Neurology 2000;55:1075-1081. 

6.

Nakamura Y, Aso E, Yanagawa H: Relative risk of Creutzfeldt-Jakob disease with cadaveric dura transplantation in Japan. Neurology 1999;53:218-220. 

7.

CDC: Update: Creutzfeldt-Jakob disease associated with cadaveric dura mater grafts - Japan, 1979-2003. MMWR 2003;52:1179-1181. 

8.

Creutzfeldt-Jakob Disease Surveillance Committee of Japan: Surveillance reports on Creutzfeldt-Jakob Disease for the fiscal year of 2006 (in Japanese). http://www.wam.go.jp (accessed December 4, 2007).

9.

Linsell L, Cousens SN, Smith PG, Knight RS, Zeidler M, Stewart G, de Silva R, Esmonde TF, Ward HJ, Will RG: A case-control study of sporadic Creutzfeldt-Jakob disease in the United Kingdom: analysis of clustering. Neurology 2004;63:2077-2083. 

10.

Nakamura Y, Yanagawa H, Hoshi K, Yoshino H, Urata J, Sato T: Incidence rate of Creutzfeldt-Jakob disease in Japan. Int J Epidemiol 1999;28:130-134. 

11.

Doi Y, Yokoyama T, Sakai M, Nakamura Y: Creutzfeldt-Jakob disease mortality in Japan, 1979-2004: analysis of national death certificate data. J Epidemiol 2007;17:133-139. 

12.

Nakamura Y, Watanabe M, Nagoshi K, Yamada M, Mizusawa H: Geographic difference of mortality of Creutzfeldt-Jakob disease in Japan. J Epidemiol 2007;17:19-24. 

13.

World Health Organization: International statistical classification of diseases and related health problems, 10th revision (ICD-10). Geneva, World Health Organization, 1992, vol 1.

14.

Japan Map Center: Directory of Location Information on Cities, Wards, Towns and Villages of Japan in the Year of 2000 (in Japanese). Tokyo, Japan Map Center, 2001.

15.

Clayton D, Kaldor J: Empirical Bayes estimates of age-standardized relative risks for use in disease mapping. Biometrics 1987;43:671-681. 

16.

Mollie A, Richardson S: Empirical Bayes estimates of cancer mortality rates using spatial models. Stat Med 1991;10:95-112. 

17.

Clayton D, Bernardinelli L: Bayesian methods for mapping disease risk; in Elliot P, Cuzick J, English D, Stern R (eds): Geographical and Environmental Epidemiology: Methods for Small-Area Studies. Oxford, Oxford University Press, 2000, pp 205-220.

18.

Kulldorff M, Nagarwalla N: Spatial disease clusters: detection and inference. Stat Med 1995;14:799-810. 

19.

Fang Z, Kulldorff M, Gregorio DI: Brain cancer mortality in the United States, 1986 to 1995: a geographic analysis. Neurooncology DOI:10.1215/S1152851703000450.

20.

D'Aignaux JH, Cousens SN, Delasnerie-Lauprêtre N, Brandel JP, Salomon D, Laplanche JL, Hauw JJ, Alpérovitch A: Analysis of the geographical distribution of sporadic Creutzfeldt-Jakob disease in France between 1992 and 1998. Int J Epidemiol 2002;31:490-495. 

21.

Cousens N, Smith PG, Ward H, Everington D, Knight RSG, Stewart G, Smith-Bathgate EAB, Macleod M-A, Mackenzie J, Will RG: Geographical distribution of variant Creutzfeldt-Jakob disease in Great Britain, 1994-2000. Lancet 2001;35:1002-1007. 

22.

Tango Y, Takahashi K: A flexibly shaped spatial scan statistic for detecting clusters. Int J Health Geographics DOI:10.1186/1476-072X.

23.

http://www.niph.go.jp/soshiki/gijutsu/download/ebpoig/index.html.

24.

http://www.niph.go.jp/soshiki/gijutsu/download/flexscan/index.html.

25.

Lee HS, Sambuughin N, Cervenakova L, Chapman J, Pocchiari M, Litvak S, Qi HY, Budka H, del Ser T, Furukawa H, Brown P, Gajdusek DC, Long JC, Korczyn AD, Goldfarb LG: Ancestral origins and worldwide distribution of the PRNP 200K mutation causing familial Creutzfeldt-Jakob disease. Am J Hum Genet 1999;64:1063-1070. 

26.

Miyakawa T, Inoue K, Iseki E, Kawanishi C, Sugiyama N, Onishi H, Yamada Y, Suzuki K, Iwabuchi K, Kosaka K: Japanese Creutzfeldt-Jakob disease patients exhibiting high incidence of the E200K PRNP mutation and located in the basin of a river. Neurol Res 1998;20:684-688. 

27.

Kawauchi Y, Okada M, Kuroiwa Y, Ishihara O, Akai J: Familial Creutzfeldt-Jakob disease with the heterozygous point mutation at codon 200 of the prion protein gene (Glu Lys) - report of CJD200 brothers of Yamanashi Prefecture origin (in Japanese). No To Shinkei (Brain and Nerve) 1997;49:460-464. 

28.

Akai J, Ishihara O, Higuchi S: Creutzfeldt-Jakob disease in Japan: an epidemiological study done in a select prefecture between 1976 and 1986. Neuroepidemiology 1989;8:32-37. 

29.

Mead S, Mahal SP, Beck J, Campbell T, Farrall M, Fisher E, Collinge J: Sporadic - but not variant - Creutzfeldt-Jakob disease is associated with polymorphisms upstream of PRNP exon 1. Am J Hum Genet 2001;69:1225-1235. 

30.

Coppedè F, Mancuso M, Siciliano G, Migliore L, Murri L: Genes and the environment in neurodegeneration. Biosci Rep 2006;26:341-367. 

31.

Collins S, Law MG, Fletcher A, Boyd A, Kaldor J, Masters CL: Surgical treatment and risk of sporadic Creutzfeldt-Jakob disease: a case-control study. Lancet 1999;353:693-697. 

32.

Sutton JM, Dickinson J, Walker JT, Raven ND: Methods to minimize the risks of Creutzfeldt-Jakob disease transmission by surgical procedures: where to set the standard? Clin Infect Dis 2006;43:757-764. 

33.

AIDS and Disease Prevention Division, Health Service Bureau, Ministry of Health and Welfare of Japan: A Manual for Clinical Practice on Creutzfeldt-Jakob Disease (in Japanese). Tokyo, Shin Nihon Kikaku Shpuppansha, 1997.

34.

Disease Prevention Study Group: A Manual for Clinical Practice on Creutzfeldt-Jakob Disease, Revised (in Japanese). Tokyo, Taiyo Bijutsu Printing Co, 2002.

  Author Contacts

Yuriko Doi, MD, MPH
Department of Education and Training Technology
National Institute of Public Health
2-3-6 Minami, Wako, Saitama 351-0197 (Japan)
Tel. +81 48 458 6111, Fax +81 48 469 0213, E-Mail yuriko@niph.go.jp

  Article Information

Received: December 31, 2007
Accepted: February 12, 2008
Published online: April 18, 2008
Number of Print Pages : 7
Number of Figures : 7, Number of Tables : 2, Number of References : 34

  Publication Details

Neuroepidemiology

Vol. 30, No. 4, Year 2008 (Cover Date: June 2008)

Journal Editor: Feigin V.L. (Auckland)
ISSN: 0251-5350 (Print), eISSN: 1423-0208 (Online)

For additional information: http://www.karger.com/NED

  Drug Dosage / Copyright

Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.